Acción ACET ADICET BIO, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Adicet Bio, Inc.

Acciones

ACET

US0070021086

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 21/06/2024 		Varia. Cinco días. Varia. 1 de enero.
1,37 USD +0,74 % Gráfico intradía de Adicet Bio, Inc. +1,48 % -27,51 %
05/06 Actualización del sector: Los valores del sector sanitario suben el miércoles por la tarde MT
05/06 Adicet Bio dice que la FDA estadounidense concede la designación de vía rápida al ADI-001 para tratar la nefritis lúpica MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Sector Update: Health Care Stocks Rise Wednesday Afternoon
Adicet Bio Says US FDA Grants Fast Track Designation for ADI-001 to Treat Lupus Nephritis
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
Adicet Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy 27th Annual Meeting
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
North American Morning Briefing : Markets Steady -2-
Adicet Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Adicet Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ACET
  4. Noticias Adicet Bio, Inc.
  5. Otros idiomas